• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Fierce Pharma Asia

Asia
Pharma

Daiichi, Eisai, Granules—Fierce Pharma Asia

Merck and Daiichi's HER3 ADC delivered a positive phase 3 result. An FDA document details shortfalls at a Granules plant in India. Plus more.
Angus Liu Sep 20, 2024 10:16am
Asia

Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia

Sep 13, 2024 8:53am
Asia

Astellas, AstraZeneca, Glenmark and more—Fierce Pharma Asia

Sep 6, 2024 9:00am
Asia

Sanofi, DualityBio, UCB—Fierce Pharma Asia

Aug 30, 2024 8:05am
Asia

J&J-Yuhan, Merck, biosecurity—Fierce Pharma Asia

Aug 23, 2024 10:05am
Asia

Merck-Curon, Legend, Amgen—Fierce Pharma Asia

Aug 16, 2024 8:59am

Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2024 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings